In the early 1920's, Canadians Fredrick Banting and Charles Best discovered insulin and set the stage for its use in the treatment of diabetes. While insulin has frequently proven effective in the management of diabetes, SciMar is now at the clinical testing stage of a program designed to detect, prevent and reverse diabetes.
This is all due to the breakthrough science of another award-winning Canadian scientist
Dr. W. Wayne Lautt of the University of Manitoba.
In 1996, Dr. Lautt identified a hormone secreted by the liver during digestion. The hormone is called "Hepatic Insulin Sensitizing Substance" or HISS.
When HISS is missing, the body becomes less effective at metabolizing food and, over time, a person will progress from pre-diabetes to diabetes.
Dr. Lautt concluded that if we could replace the HISS hormone or stimulate its secretion, we could conquer diabetes while tackling obesity and some forms of cardiovascular disease.
The breakthrough is based on many years of animal studies, verification in humans with international collaborators, and a small clinical trial.
The science has been published nationally and internationally in 40 peer-reviewed papers. The results of the clinical and animal testing have validated Dr. Lautt's hypothesis:
Replacing HISS can prevent and reverse diabetes.
To date, Dr. Lautt has attracted $9.1 million in grants and $8.2 million in private support. Operating as a private company called SciMar Ltd., Dr. Lautt and his colleagues are eager to take HISS to the next level of clinical testing in order to meet the U.S Food and Drug Administration's stringent requirements.